DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies
Arix Bioscience PLC (ARIX)
Artios announces collaboration with Novartis to create next generation DDR cancer therapies
07-Apr-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Artios announces collaboration with Novartis to create next generation DDR cancer therapies
- Artios to receive USD20 million up-front payment in addition to near term research funding to support the
collaboration.
- Artios eligible to receive up to USD1.3 billion in discovery, development, regulatory and sales-based milestones in
addition to royalty payments.
LONDON, 07 April 2021: Arix Bioscience plc ("Arix", LSE: ARIX) a global venture capital company focused on investing in
and building breakthrough biotech companies, notes that its portfolio company, Artios Pharma Limited ("Artios"), a
leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision
medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and
validate next generation DDR targets to enhance Novartis' Radioligand Therapies (RLT).
Under the three-year collaboration, Artios and Novartis will perform target discovery and validation, and Novartis will
select up to three exclusive DDR targets, and receive worldwide rights on these targets to be utilised with its RLTs.
Novartis will make an up-front payment of USD20 million and provide near term research funding to support the
collaboration. Artios will be eligible to receive discovery, development, regulatory and sales-based milestones, in
addition to royalty payments on net sales of products commercialised by Novartis. The collaboration does not include
Artios' lead programmes, ART0380, which is currently in clinical development, and ART4215, a first-in-class Pol Theta
inhibitor.
Arix is the largest shareholder in Artios, with a 12.4% ownership stake on a fully diluted basis.
Naseem Amin Executive Chairman at Arix and Artios Board Director, commented: "This collaboration will exploit Artios'
innovative discovery technology to build a pipeline of RLT combination therapies that can change the current paradigm
in cancer treatment. Following the recent multi-billion dollar deal with Merck, the collaboration with Novartis further
strengthens Artios' leadership in the field of DDR. We are proud to continue supporting Artios as it becomes a
clinical-stage precision medicine company."
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth
phase of our industry to a broader range of investors. www.arixbioscience.com
About Artios Pharma Limited
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The
Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery, including
the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK
(CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research
(ICR), London, the Netherlands Cancer Institute (NKI) and the Crick Institute, London. Artios is building a pipeline of
next-generation DDR programmes to target hard to treat cancers, including Phase I/IIa clinical studies in 2021 for its
ATR inhibitor ART0380 in treating DDR defective tumours, and the first-in-class Pol theta inhibitor ART4215 for mono
therapy and combination treatments. In December 2020, Artios entered into a collaboration agreement with Merck KGaA,
Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Merck KGaA, Darmstadt,
Germany has the right to opt into exclusive development and commercialization of compounds on up to eight targets and
Artios to receive up to USUSD860 million total milestones per target. It is backed by blue chip investors including:
AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis
Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in
Cambridge, UK, with an office in New York City, USA. www.artiospharma.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 97386
EQS News ID: 1181562
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
(END) Dow Jones Newswires
April 07, 2021 02:00 ET (06:00 GMT)
